Medical Xpress October 17, 2024
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV—short for respiratory syncytial virus—vaccine. VISION Network researchers report that across the board these vaccines were highly effective in older adults, even those with immunocompromising conditions, during the 2023–24 respiratory disease season, the first season after RSV vaccine approval in the U.S.
RSV vaccination provided approximately 80% protection against severe disease and hospitalization, Intensive Care Unit admission and death due to a respiratory infection, as well as similar protection against less severe disease in adults who visited an emergency department but did not require hospitalization, ages 60 and older. Of this population, those ages 75 and older were at...
Today's Sponsors
Today's Sponsor